Syngene International, a global leader in contract research, development and manufacturing services, continues its trajectory of growth and innovation with significant developments in recent months.
Acquisition of Biologics Manufacturing Facility: Syngene successfully concluded the acquisition of a multi-modal biologics manufacturing facility from Stelis Biopharma. The acquisition, valued at around $74m, adds 20,000l of installed biologics drug substance manufacturing capacity to Syngene’s capabilities. This acquisition includes a commercial scale, high-speed fill-finish unit, enhancing Syngene’s drug product manufacturing capabilities.
Long-Term Partnerships: Syngene signed a landmark ten-year agreement with Zoetis, a leading animal health company, to manufacture the drug substance for Librela® (bedinvetmab), a monoclonal antibody for treating osteoarthritis in dogs. This agreement, initially centred on Librela®, paves the way for development and manufacturing of other molecules in the coming years and is expected to be worth up to around $500m to Syngene over ten years, subject to regulatory approvals and market demand.
Expansion in Genome Valley, Hyderabad: Syngene unveiled plans to expand its operations in Genome Valley, Hyderabad, with the purchase of a 17-acre land parcel. The new facilities, set to commence construction this year, will accommodate state-of-the-art research laboratories, creating up to 1,000 jobs in the next five years. This expansion aligns with Syngene’s commitment to drive innovation and contribute to the growth of the biotech industry.
Syngene’s existing research facility in Genome Valley was inaugurated in 2020 and accommodates over 900 scientists. The research carried out on the site focuses on discovery, chemistry and biology, primarily for the global pharmaceutical industry. The site also includes a PROTAC laboratory that conducts leading-edge research into disease-causing proteins, which lie at the heart of diseases such as cancer, as well as a Central Compound Management facility, which serves as a central storage facility for all compounds synthesised by Syngene scientists.